Other Events ·
Veradermics reports positive Phase 3 Study '302' data for VDPHL01 in male pattern hair loss
MANEVeradermics, Inc
Veradermics announced positive topline results from Part B of its registration-directed Phase 2/3 clinical trial (Study ‘302’) evaluating VDPHL01, an investigational oral minoxidil formulation, in over 500 males with mild-to-moderate pattern hair loss. At Month 12, participants receiving twice-daily dosing showed a non-vellus hair count increase of 43.9 hairs/cm², while once-daily dosing maintained growth at 29.7 hairs/cm². The treatment demonstrated a favorable safety profile with no new signals or cardiac adverse events. Veradermics is a late-stage biopharmaceutical company developing innovative therapeutics for pattern hair loss.